Irish High Court Sets Hearing to Sanction Alkermes Acquisition of Avadel Pharmaceuticals
Summary
Avadel Pharmaceuticals announced that the High Court of Ireland has scheduled a hearing for February 10, 2026, to sanction the proposed acquisition by Alkermes plc, signaling the final stages of the deal.
Key Events
-
Court Hearing Scheduled for Acquisition Sanction
The High Court of Ireland has set a Sanction Court Hearing for February 10, 2026, to consider the application to sanction the proposed scheme of arrangement for Alkermes plc to acquire Avadel Pharmaceuticals plc.
-
Acquisition Nearing Completion
The acquisition is expected to close shortly after the Court issues an order sanctioning the Scheme, indicating the final stages of the transaction.
-
Public Notification for Interested Parties
Interested parties intending to appear at the hearing must notify Avadel's solicitors by February 5, 2026, and indicate whether they support or oppose the application.
Analysis
The scheduling of the Sanction Court Hearing is a critical procedural step towards the completion of Alkermes plc's acquisition of Avadel Pharmaceuticals. This indicates that the acquisition process is nearing its final stages, with the closing expected shortly after the court issues its order. For investors, this significantly reduces the uncertainty surrounding the deal and provides a clear timeline for its conclusion, reinforcing the investment thesis based on the acquisition terms.
At the time of this filing, AVDL was trading at $21.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.38 to $23.57. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.